Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-01-26
1996-06-11
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 12, 514921, 424DIG13, 530350, A61K 3702, C07K 710, C12N 1500, C12P 2102
Patent
active
055255930
DESCRIPTION:
BRIEF SUMMARY
In connection with extensive research in experimentation it has now surprisingly been found that IGF-II effectively promotes regeneration of muscle tissue, whereas IGF-I does not. Thus, experiments in vivo on rate show that IGF-II significantly promotes regeneration of muscle tissue thus making the peptide useful in the treatment of muscle tissue. A similar experiment concerning wound healing in cardiac muscle unexpectedly showed increased healing and/or decreased scar formation. This is a new finding since it is established knowledge that cardiac tissue does not regenerate.
Accordingly, it is the main object of the present invention to provide new techniques for preparing medicaments effective in improving the regeneration of muscle tissue.
Another object of the invention is to provide for a medicament useful in the healing of cardiac muscle tissue.
A third object of the invention is to provide techniques for preparing a medicament for use in the healing of smooth muscle tissue, such as intestinal smooth muscle tissue.
Still another object is to provide a method for medical treatment for the purpose of regenerating muscle tissue.
Accordingly, the invention resides in the use of IGF-II for preparing a medicament for the regeneration of muscle tissue. According to a preferred aspect of the invention such use is directed to the preparation of a medicament for use in the healing of cardiac muscle tissue. An alternative aspect of the invention resides in the use of IGF-II for preparing a medicament for use in the healing of intestinal smooth muscle tissue.
The invention also resides in a method for medical treatment resulting in improved regeneration of muscle tissue. Said method includes the step of administering to a patient in need of corresponding treatment an effective amount of IGF-II.
The medicinal composition used in accord with the present invention may thus in accordance with traditional pharmaceutical practice be formulated for use in human or veterinary medicine for therapeutic purposes. Such compositions may include the active ingredient IGF-II in combination with a pharmaceutically acceptable carrier, which may be solid, semisolid or liquid.
The compositions include those in a form adapted for topical application but may also be designed for administration through other routes.
Suitable forms of the composition used in applying the techniques of the present invention include tablets, capsules, syrups, suspensions, solutions and forms suitable for injection or infusion. The latter forms intended for injection or infusion are preferred. Such compositions may contain conventional pharmaceutically acceptable materials, such as diluents, binders, colors, flavors, preservatives, disintegrates and the like in accordance with conventional pharmaceutical practice in a manner well understood by those skilled in the art of formulating drugs.
Injectable or infusable compositions of IGF-II are particularly suitable as levels of IGF-II can occur after administration by injection or infusion at the site of muscle tissue subject to regenerative healing. A particularly preferred site for cardiac treatment is the pericardium, and the administration can take different forms, such as infusion or implantation of a slow release formulation containing IGF-II.
The administered does of the active ingredient, IGF-II, may vary between broad limits, but a preferred range may be between about 0.1 and about 10 mg per day for a week. The dose is, of course, dependent on the degree and type of damage, type and condition of the patient and will be determined from case to case.
The present invention will be further illustrated in the following by specific examples which are not to be construed as limiting the scope of the invention otherwise than the definition in the appended claims. This illustration of the invention will be made with reference to the appended drawings, wherein:
FIGS. 1a, 1b and 1c illustrate sections through frozen tissue samples, FIG. 1a being control sample. FIG. 1b sample after treatment with IGF-I and FIG.
REFERENCES:
patent: 4783524 (1988-11-01), Larsen et al.
patent: 4861757 (1989-08-01), Antoniades et al.
patent: 4885163 (1989-12-01), Shaar et al.
patent: 4939135 (1990-07-01), Robertson et al.
patent: 4981956 (1991-01-01), Larsen et al.
patent: 4983581 (1991-01-01), Antoniades et al.
patent: 5019559 (1991-05-01), Antoniades et al.
patent: 5035887 (1991-07-01), Antoniades et al.
patent: 5057494 (1991-10-01), Sheffield
patent: 5089475 (1992-02-01), Wilmore
patent: 5124316 (1992-06-01), Antoniades et al.
patent: 5166191 (1992-11-01), Cronin et al.
patent: 5229493 (1993-07-01), Folkman et al.
patent: 5256644 (1993-10-01), Antoniades et al.
Dialog Information Service, file 155, Medline, 66-91, Dialog Acc. No. 07206852, T. P. White et al., "Satellite Cell and Growth Factor Involvement in Skeletal Muscle Growth", Med Sci Sports Exerc, Oct. 1989, 21 (5 Suppl), pp. 158,163.
The Journal of Cell Biology, vol. 110, Apr. 1990, Pico Caroni et al., "Nerve Sprouting in Innervated Adult Skeletal Muscle Induced by Exposure to Elevated Levels of Insulin-Like Growth Factors", pp. 1307-1317.
17th Annual Meeting of the Society for Neuroscience--Insulinlike Growth Factor-II Gene Expression in Muscle: "Relationship to Synapse Elimination and Nerve Regeneration", D. N. Ishii, New Orleans, Louisiana, USA, Nov. 16-21, 1987, Soc. Neurosci. Abstr. 13(2), 1987.
Acta Physiol Scand, vol. 130, 1987, E. Jennische et al., "Regenerating Skeletal Muscle Cells Express Insulin-Like Growth Factor I", pp. 327-332.
Chemical Abstracts, vol. 108, No. 21, May 23, 1988, (Columbus, Ohio, US), Robert S. Bar et al., "IGF-Receptors in Myocardial Capillary Endothelium: Potential Regulation of IGF-I Transport to Cardiac Muscle", p. 163, Abstract 180989j, & Biochem. Biophys. Res. Commun. 1988, 152(1), 93-98.
Jennische Eva
Lake Mats
Griffin Ronald W.
Pharmacia AB
LandOfFree
Medicinal use of IFG-II does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicinal use of IFG-II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal use of IFG-II will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-351712